Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma
Keywords: 
Multiple myeloma
Minimal residual disease
Hemodilution
Issue Date: 
2021
ISSN: 
2072-6694
Note: 
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https: //creativecommons.org/ licenses/ by/ 4.0 /).
Citation: 
Puig, N.; Flores-Montero, J.; Burgos-Rodríguez, L. (Leire); et al. "Reference values to assess hemodilution and warn of potential false-negative minimal residual disease results in myeloma". Cancers. 13 (19), 2021, 4924
Abstract
Although the majority of patients with myeloma who achieve undetectable minimal residual disease show prolonged survival, some of them relapse shortly afterwards. False-negative results due to hemodiluted bone marrow samples could explain this inconsistency, but there is no guidance on how to evaluate them. We analyzed three cell populations normally absent in peripheral blood in 1404 aspirates obtained in numerous disease settings and in 85 healthy adults. Pairwise comparisons according to age and treatment showed significant variability, thus suggesting that hemodilution should be preferably evaluated with references obtained after receiving identical regimens. Leveraging the minimal residual disease results from 118 patients, we showed that a comparison with age-matched healthy adults could also inform on potential hemodilution. Our study supports the routine assessment of bone marrow cellularity to evaluate hemodilution, using as reference values either treatment-specific or from healthy adults if the former are unavailable.

Files in This Item:
Thumbnail
File
Reference values.pdf
Description
Size
4.5 MB
Format
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.